Levetiracetam Solution
Product Images NDC 16714-358

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 16714-358). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Levetiracetam Fig1)

Figure 1 (Levetiracetam Fig1)
The text is a figure caption showing responder rates in Study 1, with percentages of 39.6% and 37.1% for two groups labeled as "Ll" and "Pcabo", respectively. There is also a note indicating that the Pcabo group was statistically significant compared to placebo.*
FDA Label Image

Figure 2 (Levetiracetam Fig2)

Figure 2 (Levetiracetam Fig2)
The text describes a figure called "Responder Rate" with results displayed as percentages for a study called "Study 2" in a period called "Period A". There are three percentages given as results, 35.2%, 208%, and 63%, and a comparison is made with a drug called Leveraceam and a placebo. The text appears to be part of a scientific or medical report.*
FDA Label Image

Figure 3 (Levetiracetam Fig3)

Figure 3 (Levetiracetam Fig3)
FDA Label Image

Figure 4 (Levetiracetam Fig4)

Figure 4 (Levetiracetam Fig4)
The text describes a figure showing the responder rate (>50% reduction from baseline) in Study 4. The figure shows percentage values ranging from 0% to 44.6% with a sample size of 97 patients who received the placebo. There is also a note stating that the result was statistically significant versus placebo.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
This is a figure showing the responder rate for patients aged 1 month to <4 years in Study 5. The responder rate is a 50% reduction from baseline. The placebo group (N=51) had a responder rate of 19.6%, while the levetiracetam group (N=58) had a responder rate of 43.5%, which is statistically significant versus placebo.*
FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
The text describes a figure (Figure 6) presenting the percentage of patients who responded (>50% reduction from baseline) to a treatment for PGTC seizure frequency per week in Study 7. The figure shows that 72.2% of patients who received Levetiracetam responded to the treatment compared to only 45.2% of patients who received placebo (N=84 and N=79 respectively). The text also specifies that the difference is statistically significant.*
FDA Label Image

Package Label-principal Display Panel (100 mg/mL (473 mL Bottle))

Package Label-principal Display Panel (100 mg/mL (473 mL Bottle))
FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical Structure (Levetiracetam Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.